StockNews.com Begins Coverage on TherapeuticsMD (NASDAQ:TXMD)

Analysts at StockNews.com began coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research note issued to investors on Tuesday. The firm set a “hold” rating on the stock.

TherapeuticsMD Stock Performance

NASDAQ:TXMD opened at $1.04 on Tuesday. The firm has a fifty day simple moving average of $1.27 and a two-hundred day simple moving average of $1.55. TherapeuticsMD has a 12 month low of $0.70 and a 12 month high of $2.75.

Institutional Investors Weigh In On TherapeuticsMD

An institutional investor recently raised its position in TherapeuticsMD stock. Clearline Capital LP raised its holdings in TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 636,622 shares of the company’s stock after buying an additional 101,282 shares during the period. Clearline Capital LP owned about 5.52% of TherapeuticsMD worth $1,025,000 as of its most recent filing with the Securities and Exchange Commission. 30.74% of the stock is owned by institutional investors and hedge funds.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.